
Fortress Biotech, Inc. (NASDAQ:FBIO – Free Report) – Equities researchers at HC Wainwright issued their Q4 2026 earnings per share (EPS) estimates for shares of Fortress Biotech in a report released on Tuesday, November 17th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($0.15) for the quarter.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%. The company had revenue of $19.16 million during the quarter, compared to analyst estimates of $21.57 million.
Several other equities analysts also recently weighed in on FBIO. Wall Street Zen downgraded shares of Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings lowered shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $17.00.
View Our Latest Stock Report on FBIO
Fortress Biotech Price Performance
NASDAQ FBIO opened at $1.82 on Wednesday. The company has a quick ratio of 3.83, a current ratio of 2.93 and a debt-to-equity ratio of 0.10. The company has a market cap of $61.41 million, a PE ratio of 0.79 and a beta of 1.27. Fortress Biotech has a 52 week low of $1.64 and a 52 week high of $4.53. The firm’s 50-day simple moving average is $2.10 and its two-hundred day simple moving average is $2.71.
Hedge Funds Weigh In On Fortress Biotech
A number of large investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in shares of Fortress Biotech during the 3rd quarter valued at $462,000. Renaissance Technologies LLC lifted its holdings in Fortress Biotech by 22.8% during the 1st quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 18,490 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Fortress Biotech during the 2nd quarter worth about $47,000. 96.51% of the stock is owned by institutional investors.
About Fortress Biotech
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
See Also
- Five stocks we like better than Fortress Biotech
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
